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DockingTwo new fluorophenylindenone derivatives were designed as potential p38a MAPK modulators by pre-
serving the key interactions of the vicinal pyridine/fluorophenyl pharmacophore with the enzyme pro-
tein. Interestingly, these two fluorophenylindenone isomers showed divergent activities, with
compound 6 behaving as an inhibitor and 5 as a putative activator. These results were rationalized by
docking studies and molecular dynamics simulations in terms of stabilization of DFG loop, by compound
5 in a conformation more accessible to phosphorylation.
 2016 Elsevier Ltd. All rights reserved.Mitogen-activated protein kinases (MAPK) are protein kinases considered an interesting target for the development of anti-
that can be classified in several distinct groups composed of sets
of three evolutionarily conserved, sequentially acting kinases:
MAPK, MAPK kinase (MKK), and MKK kinase (MAP3K).1–3 The acti-
vation of MAP3K leads to phosphorylation and activation of an
MKK, which in turn stimulates MAPK activity through dual phos-
phorylation on threonine and tyrosine residues located in the acti-
vation loop. Once activated, MAPK phosphorylate cytoplasmic and
nuclear target substrates on serine or threonine residues.
p38 proteins are a class of MAPK playing a crucial role in impor-
tant cellular processes (i.e. cell differentiation, apoptosis, and
autophagy) and are responsive to stress stimuli such as heat and
osmotic shock, ultraviolet irradiation, and inflammatory cytokines.
The p38 MAPK family includes four different isoforms, namely
p38a, p38b, p38c, p38d.4 Among them, p38a has been reported
to be largely expressed in monocytes and macrophages, whereas
p38b is abundant in endothelial cells, p38c in skeletal muscle,
and p38d in testes, pancreas, prostate, small intestine and in
certain endocrine tissues.5 Substrates of p38 MAPKs include a
large number of different proteins and a significant portion of them
is involved in the regulation of gene expression.6 p38 has beeninflammatory drugs.7–10 Thus, over the past two decades, the
development of small molecule p38aMAPK inhibitors has received
an extraordinary level of attention both in the pharmaceutical
industry and in the academia. Thus, the medicinal chemistry work
has produced a large number of inhibitors (see Fig. 1 for some rep-
resentative structures), and some of them have been co-crystal-
lized with the enzyme in order to evaluate the drug-protein
interactions in the complexes.11
The most explored chemical class of p38a MAPK inhibitors is
characterized by the presence of a nitrogen-containing six member
heterocyclic moiety (pyridine, pyrimidine, or equivalents) in a vic-
inal position to a lipophilic (most often a p-fluorophenyl) group.
The development of this family of compounds has been stimulated
by the interesting results obtained with compound 1 (SB203580)
and its congeners by SmithKline Beecham.12 The exploration of
the chemical space around this structure has produced inhibitors
showing potency in the nanomolar range and the discovery of 4-
azaindole derivatives 4a,b.13
In order to evaluate the effects of further core modifications on
the interaction with p38a, fluorophenylindenone derivatives 5 and
6 (Fig. 1) were designed by replacing the imidazole heterocyclic
core of 1 with the indenone scaffold. The central pharmacophore
consisting in the vicinal pyridine/fluorophenyl system was
Figure 1. Comparison of the structures of the newly designed isomeric indenone
derivatives 5 and 6 with those of some selected p38a MAP kinase inhibitors.
Figure 3. MAPK14 (p38a) phosphorylation in the presence of compound 5 and
different ATP concentrations, 100 lM or 500 lM (close to the Km value). Data are
expressed as mean ± SEM.
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gen bond acceptor for the NH of Met-109 and the 4-fluorophenyl
moiety could occupy the hydrophobic back pocket. On the other
hand, the indenone moiety of 5 and 6 could find different accom-
modations in the phosphate/sugar region of the binding site.
Compounds 5 and 6 were synthesized as described in the Sup-
porting information, characterized by crystallography [CCDC
1487925 (5), 1487926 (6), see Supporting information], and tested
for their potential modulatory activity on p38a MAPK enzyme at
Life Technologies Ltd14 [SelectScreen Kinase Profiling, Protein Ser-
ine/Threonine Kinase MAPK14 (p38a) direct Z-LITE kinase assays
platform, for the experimental details see http://www.lifetech-
nologies.com/selectscreen] by using two different ATP concentra-
tions, namely 500 lM (close to the Km value) and 100 lM.15
In the enzymatic studies, indenone derivative 6 showed signif-
icant inhibitory properties, with a potency in the micromolar range
that appeared to be dependent by the concentration of ATP used in
the enzymatic assay (Fig. 2).
In particular, with the ATP concentration close to the Km value
the concentration–effect curve for compound 6 is slightly shifted
to right compared with that observed with a lower ATP concentra-
tion. Accordingly the IC50 value in the presence of 500 lM ATP was
slightly but significantly higher (1.35 lM vs 0.899 lM, for 500 and
100 lM ATP, respectively).
On the other hand, isomeric indenone 5 failed in showing an
inhibitory activity at both the ATP concentrations tested. Surpris-Figure 2. MAPK14 (p38a) phosphorylation in the presence of compound 6 and
different ATP concentrations, 100 lM or 500 lM (close to the Km value). Data are
expressed as mean ± SEM.ingly on the contrary, at the ATP concentration corresponding to
the Km value, compound 5 appeared to increase MAPK14 phospho-
rylation, thus behaving as a partial activator (activation effect
around 40–50% at 10 lM, Fig. 3).
In order to verify this surprising result, compound 5 was re-
sampled and re-assayed in the same test system and the results
confirmed those obtained in the preliminary assay. In fact, the
top three concentrations induced a significant increase of phospho-
rylation. This phenomenon could be caused by compound-depen-
dent activation of the kinase, or by undetected assay interference
of some sort. In order to rule out fluorescence interferences and
development reaction interferences, control wells were used and
compound 5 did not show any evidence of interference. On the
other hand, the activation effect appeared to be almost negligible
at 100 lM ATP, suggesting the importance of the ATP concentra-
tion in revealing the activation features of indenone derivative 5.
Thus, the preliminary results of the enzymatic studies per-
formed with compound 5 was surprising because this indenone
isomer of the p38a MAPK inhibitor 6 appeared to behave as
activator.
Owing to these intriguing results, docking studies and molecu-
lar dynamics simulations were performed in order to rationalize
the apparently divergent behavior obtained with the isomeric
indenone derivatives. Docking of compounds 5 and 6 to p38a
MAPK was performed on the basis of the structural similarity of
these compounds with the 4-azaindole inhibitor 4b (type I
inhibitor),11 the crystal structure of which, in complex with p38a
MAPK, has been resolved (PDB code :1OZ1, Fig. 4).13Figure 4. 4-Azaindole inhibitor 4b bound to p38a MAPK (PDB code: 1OZ1).13
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idine nitrogen of the 4-azaindole inhibitor 4b behaved as the
hydrogen bond acceptor for the NH of Met109, the 4-fluorophenyl
moiety occupied the hydrophobic back pocket called hydrophobic
region I (HR-I), and the 4-azaindole moiety was capable of direct
hydrogen bonding the terminal nitrogen of Lys53. The hydrogen
bond with Lys53 was claimed to be required for the regioselective
positioning of the pyridine and the 4-fluorophenyl groups.16Figure 5. Docking of compound 5 (top) and 6 (bottom) to p38a. DFG loop is in the
‘in’ conformation (binding mode of type I inhibitors).
Figure 6. 3D structure of complexes between the compound 5 (left) and 6 (rigTherefore, in the docking of compounds 5 and 6 we assumed
that the ligands target the ATP binding site of the enzyme in its
active form. The active form of the enzyme is characterized by an
open conformation of the activation loop (DFG-loop), which is usu-
ally referred to as DFG ‘in’ on the basis of the position of the Phe169
residue belonging to the conserved triad Asp168-Phe169-Gly170
at the beginning of the activation loop.17–19
As expected, fluorophenylindenone derivatives 5 and 6 (Fig. 5)
maintained the key interactions of type I inhibitors. In particular,
a hydrogen bond is established between pyridine nitrogen and
the amide proton of Met109, and significant hydrophobic interac-
tions involve the 4-fluorophenyl group with hydrophobic region I.
HR-I is located at the back of the ATP binding site, and is defined by
Ala51, Lys53, Leu75, Ile84, Leu104, Thr106 and Leu167.11
Most importantly, compound 6 also accepts a hydrogen bond
from Lys53 (Fig. 5). On the contrary, in compound 5 the oxygen
acceptor of H-bond is located at the opposite side, preventing the
achievement of this interaction (Fig. 5), which is necessary to
engage the inhibitor in loco.13,16 This may trigger the different
behaviour of the two ligands in the enzymatic essay. In fact, a
marked conformational change upon binding of compound 5 is
observed for Arg173, which moves away from Tyr35 of the Gly–
loop (aa res. 31–37) and establishes a network of strong electro-
static interactions with Asp168 and Glu178 of the DFG loop. Con-
sequently, the binding site is more accessible, being the gateway
of the binding pocket around 3 Å larger, the DFG motif is stabilized
in its active DFG-in conformation and the phosphorylation sites
more accessible (Fig. 6).
In conclusion, two new fluorophenylindenone derivatives (5
and 6) were designed from p38a MAPK inhibitor 1 by replacing
its imidazole heterocyclic core with indenone scaffold and conserv-
ing the central pharmacophore (i.e. the vicinal pyridine/fluo-
rophenyl system). In our working hypothesis, the pyridine
nitrogen of 5 and 6 could behave as the hydrogen bond acceptor
for the NH of Met-109, the 4-fluorophenyl moiety could occupy
the hydrophobic back pocket, and the indenone moiety could find
different accommodations in the phosphate/sugar region of the
binding site. The fluorophenylindenone isomers 5 and 6 were syn-
thesized, characterized by X-ray crystallography, and tested for
their potential modulatory activity on p38a MAPK enzyme by
using two different ATP concentrations. In these studies, com-
pound 6 behaved as an inhibitor, whereas isomeric indenone 5,
at the ATP concentration corresponding to the Km value, appearedht) and p38a MAPK, as resulted from the molecular dynamics simulation.
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rationalized by docking studies, which showed that compounds 5
and 6 retained the typical interactions of type I inhibitors, as
expected. The main difference was the absence of the hydrogen
bond interaction from Lys53 in the complexes of activator 5 that
produced a remarkable conformational change resulting in the
stabilization of DFG loop in a conformation more accessible to
phosphorylation.
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